The Leadership Team at Panavance Therapeutics Inc. is responsible for steering the company’s strategic direction, overseeing clinical and commercial operations, ensuring financial stability, and fostering key academic and industry partnerships to advance the development and global distribution of the novel oncology therapeutic, GP-2250.